Research library
Cognitive & NeuroprotectivePreclinical / anecdotal
Angiotensin IV analog (Nle1-AngIV derived)
Dihexa, Procognitive synaptogenic compound
An angiotensin IV analog reported in preclinical models to be a potent procognitive/synaptogenic compound acting via HGF/c-Met signaling.
Ang IV
HGF / c-Met
0
How Dihexa works
An angiotensin IV derivative engineered for the brain, reported in preclinical models to drive synapse formation via HGF/c-Met. Entirely preclinical, with no human data.
Dihexa
HGF / c-Met
Synaptogenesis
Cognition
Research applications
Cognition / synaptogenesis
Preclinical
Alzheimer's
Neuroprotection
Bars indicate how far the evidence has progressed (in vitro to animal to human), not the size of any effect.
Molecular profile
Evidence, safety & status
Claimed benefits & evidence
Preclinical only; touted for Alzheimer's/cognition. No human trials, the 'potent synaptogenesis' claims are from preclinical assays, not clinical outcomes.
Safety & dangers
Potent synaptogenesis/HGF-c-Met activation raises a theoretical oncogenic concern (c-Met is an oncogene); human safety unknown.
Regulatory status
Not FDA approved; Category 2 (2023), removed April 2026; slated for a later PCAC meeting (by Feb 2027). WADA: S0.
Source: Fnx Performance Peptide Research Database, a synthesis of the scientific and regulatory literature, not medical advice. For medical questions, consult a qualified physician.
For research use only
For Research Use Only. Not for human or animal consumption. Products are sold strictly for in vitro laboratory research, not for compounding or therapeutic application.